Something in the air: Hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy

Research output: Contribution to journalShort surveypeer-review

Abstract

Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway. Recent clinical trials in cancer therapy have demonstrated unprecedented responses through blockade of CTLA-4 and PD-1 immune checkpoint pathways. In a provocative recent paper in Science Translational Medicine, Hatfield and colleagues demonstrate the ability of supplemental oxygen to act as a novel immune checkpoint inhibitor by disrupting the hypoxia-adenosine-A2aR pathway.

Original languageEnglish (US)
Pages (from-to)435-436
Number of pages2
JournalCancer cell
Volume27
Issue number4
DOIs
StatePublished - Apr 13 2015

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Something in the air: Hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapy'. Together they form a unique fingerprint.

Cite this